在1型糖尿病患者中胰岛素和胰高血糖素同步给药可预防低血糖且不增加高血糖
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
关键信息
- 低血糖症仍然是接受胰岛素治疗患者代谢控制的最大障碍，而这反过来又会造成长期的健康不良结局。
- 新近研究表明，在一定血浆浓度下同步使用肽激素是可行的，可调控过多的高血糖和低血糖偏移。
- 1型糖尿病患者混合餐负荷后，以固定摩尔比联合使用（IV）胰岛素和胰高血糖素并未显示出安全隐患，并且所有患者对治疗的耐受性都很好。
- 所有过去曾经历低血糖的患者，在本疗法中餐后血糖无明显升高，低血糖风险显著降低。
- 这种新疗法是基于对两种糖调节肽之间复杂关系的日益了解，从而拓宽了胰岛素的治疗范围并降低了低血糖风险，而低血糖是糖尿病患者最大的恐惧。
- 这种方法为安全有效且简化的治疗方法打开了大门。
Presenting Author
Disclosures
B. W. Bode: Advisory Panel; Self; Medtronic, Novo Nordisk A/S, Consultant; Self; Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Research Support; Self; Abbott, Advance, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Insulet Corporation, Janssen Pharmaceuticals, Inc., MannKind Corporation, Medtronic, National Institutes of Health, Nova Biomedical, Novo Nordisk A/S, Provention Bio, Inc., Sanofi, Senseonics, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., MannKind Corporation, Medtronic, Novo Nordisk A/S, Sanofi, Senseonics, Stock/Shareholder; Self; Aseko.
